V GROUP'S PUBLICATION :

The Pharma Jukebox

VOLUME I, ISSUE 5 | SEPTEMBER, 2011 NEWSLETTER

"I do not fear, as I have hope.
I do not doubt, as I have faith."
-Vishal Jajodia
CEO

From the editor's desk:

The average time from the identification of a drug target to approval of a new drug application (NDA) has increased significantly, from an average 7.9years to 12.8years.

Much of the increase is due to increase in clinical trial length; in addition, the average number of procedures performed on patients has increased by 118% in Phase II clinical trials and 51% in Phase III clinical trials.

This edition of "The Pharma jukebox" highlights the regulatory hurdles faced by pharmaceutical companies. It also talks about why old molecules with safety and efficacy established will rule the future of pharmaceutical companies.

I welcome all your suggestions, comments and criticisms.

Sanaa Jummal
Editor

Feedback At:

Email: pr@spentose.com

Contact Details:
+91- 22- 61505208

Drying Drug Pipelines: A matter of Concern!

"The operating environment for pharma is worsening rapidly. If the pharma sector is under-capitalized, then we will be under-medicalized."

- Anonymous

"The operating environment for pharma is worsening rapidly". That's a quote from a Morgan Stanley research document. The shrinkage is due in part to a drying-up pipeline–a drying-up exacerbated, ofcourse, by the trial lawyers and the FDA and also to other factors , such as the rise of generics. Some 75percent of prescriptions drugs consumed in the US are generic.

In 1980's, a drug was made available to the market at a cost of USD132million, which now has risen to USD1.8billion. Despite advancements in drug discovery technology, experiences and efficiencies of scale, the price has increased by almost 15times.

The competitive nature of the pharmaceutical industry and the high costs associated with drug development has placed great demands on improving the efficiency of drug discovery. Recent statistics indicate that the attrition rates during drug development remain high.

The complex, lengthy, and unpredictable nature of drug R&D certainly contributes significantly to high costs and inefficiencies. But this seems to be costing the life of every patient.

We are committed to bringing new health solutions to the suffering patients in the various areas of neglected disease, by partnering with leading scientists at globally renowned research institutes, bringing to market drugs with well established safety over decades for new therapeutic applications in the space on neglected diseases, keeping in line with our commitment of social responsibility by not patenting the new opportunity and opening the market globally for all.

For sure this will open a new world business format, if not anything will surely bring down the cost and risk profile considerably and also make profits for reinvestment in new areas.

For more details, visit us at:

www.spentose.com
www.comfora.in
www.comforachemist.in

We would like to hear from you. Send in your feedback at **pr@spentose.com**

Swati Spentose Pvt. Ltd

- *Swati Spentose Pvt Ltd, is a subsidiary of the 40 year old Euresian group.*
- *Swati Spentose has established unique-cutting edge technology platforms in the development of Polysaccharides bio-generics, in collaboration with world renowned research platforms like Mt Sinai School of Medicine and clinicians and scientists world over.*
- *The key therapeutic areas of Swati Spentose include urology, chronic progressive vascular disease and diabetes among others.*

Our Basket of Finished Dosages:

Dutride T
Tamsulosin 0.4mg + Dutasteride 0.5mg Capsule

Dutride T

Dutride
Dutasteride 0.5 mg Soft Gelatin Capsules

Dutride



Comfora

Terod
Tolterodine Tartrate 2 mg Tablets

Terod

FinFlow
Finasteride 5 mg Tablets

FinFlow

We offer following API's from USFDA, EDQM, UKMCA, TGA Australia, MCC-South Africa approvable site :

- Pentosan Polysulfate sodium
- Dextran Salts
- Hydroxyl Ethyl Starch
- Lidocaine HCl / Base
- Meloxicam
- Phenytoin Base / Sodium

For further information contact : **api@spentose.com**

SWATI SPENTOSE PVT.LTD.

114,Marine Chambers,
11,New Marine Lines,
Mumbai-400 020.India.
Tel-0091-22-66332427
Fax-0091-22-22071955

For more information visit us at : *www.spentose.com*

Or Drop in a mail at pr@spentose.com

Or Give us a call at the number mentioned to the left